Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 31, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 3, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-140137
Filed / recorded
Apr 3, 2026, 12:15 AM UTC
Added to OQRO
Oct 8, 2026, 8:56 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
BELITE BIO, INC
Issuer CIK
1889109
Ticker
BLTE
Reporting person
Yu-hsin Lin
Relationship
Director, Officer
Officer title
Chief Executive Officer
Security
Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Mar 31, 2026
Transaction code
A
Shares / units
206,954
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
413,908
Ownership form
Direct
Amendment
No
Footnotes from the filing
On December 23, 2020, the reporting person was granted an option which shall vest in installments upon satisfaction of certain performance criteria. 206,954 ordinary shares subject to the option that had previously vested remain exercisable. One of the performance criteria was met on 3/31/2026, resulting in vesting of the option as to additional 206,954 ordinary shares.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.